BBNX · Beta Bionics Inc Q2 FY2026 earnings call record财报电话会记录

“Getting down to business, today we're going to cover our financial results for the second quarter, updated guidance for the full year 2026, some recent developments in our innovation pipeline.”

“Starting with a brief overview of our Q2 performance, we delivered $32 million in net sales, which grew approximately 38% year-over-year.”

“Our gross margin was 59%, expanding 524 basis points year-over-year.”

“Moving on to gross margin, Q2 gross margin was 59.0%, declining 45 basis points relative to the prior quarter and increasing 524 basis points relative to Q2 2025.”

“We are reiterating our guidance for total revenue of $131 million-$136 million, as well as our expectation that 37%-39% of our new patient starts will be reimbursed through the pharmacy channel.”

“On gross margin, we are raising our full year outlook to 58.5%-59.5%, up from our prior guidance of 57.5%-59.5%.”

“In the coming quarters, we intend to initiate a fully closed loop pivotal trial in type 1 and type 2 diabetes and pursue the indication formally with the FDA.”

“The iLet is resonating with customers and delivering outstanding clinical outcomes.”

“The softness that you're seeing in pharmacy supply revenue in the second quarter is driven by what I call a stocking dynamic from our pharmacy customers.”

“What I mean by this is that our pharmacy customers ended the second quarter with less pharmacy supply inventory on their shelf than they did at the end of Q1.”

“The actual revenue can be pretty dramatically impacted based on ordering patterns from the pharmacy customers, and that's what drove that dynamic.”

“Point is, you could have another company selling something similar, one of our competitors selling something similar to similar customers, and our performance wouldn't necessarily dictate what their particular performance was in terms of stocking in the exact same quarter.”